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obtained from the derivation versus the validation samples. The
construct validity of the DRCI was assessed by comparing it to
only demographics, a comorbidity-index, and the revised
Chronic Disease Score (CDS). Wilcoxon matched-pairs signed-
rank test was used to determine differences between the median
squared residual scores between the various risk-adjustment
models. RESULTS: The correlation between actual and predicted
costs between the derivation and validation samples was not sta-
tistically different for the three predicted outcomes. Age and sex
accounted for 0.8% and 0.1% of the variance in total and ambu-
latory cost. The comorbidity index and the CDS individually
explained approximately 6%–10% of the variance in total and
ambulatory cost, respectively. The DRCI explained 6%–8% of
the variance in total and ambulatory costs, and did signiﬁcantly
(p < 0.05) better than only demographics. The added variance
explained by the incorporation of the comorbidity index or CDS
accounted for 5%–8% of the variance in total and ambulatory
costs, respectively. CONCLUSIONS: The predictive validity of
the DRCI is equivalent to that of the CDS. When the DRCI was
used along with the CDS, up to eight percent of variability in
costs and utilization were explained. This may suggest that the
DRCI and the CDS may be explaining different dimensions of a
subject’s severity of diabetes.
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OBJECTIVES: The ﬁfth leading cause of death by disease in the
U.S., type-2 diabetes places patients at higher risk for heart
disease, blindness, kidney failure, extremity amputations, and
other chronic conditions. The 2002 costs associated with dia-
betes were estimated at US$132 billion. Predictive models incor-
porating clinical measures of diabetes severity from clinical
databases and their association to health care resource use and
costs are needed for health plan resource planning and man-
agement. The purpose of this study was to determine the 
relationship between health care resource use and costs with dia-
betes-related clinical measures, and to develop a diabetes
resource consumption index (DRCI). The DRCI consists of
empirically derived weights to predict health care use among
persons with diabetes. METHODS: The data was collected from
four outpatient clinics within the Southern Arizona Veterans
Affairs Health care System. The DRCI models used diabetes
severity measures to predict three health care resource outcomes:
risk of hospitalization; total health care costs; and ambulatory
costs. Severity of diabetes was deﬁned as the function of annual
HbA1C, creatinine clearance-rate, and cholesterol values.
Comorbidity was deﬁned as the number of concurrent secondary
diseases. The log-likelihood ratio test and the Wald test-statistic
were used to assess the performance of the models. RESULTS:
A total of 367 diabetic subjects had complete information on
diabetes-speciﬁc variables and represented the sample for this
study. DRCI weights based on the magnitude of one year health
care resource use and socio-demographic characteristics, ranged
from -471.5 to 3081.2 for total health care costs, from -304.3
to 1582.1 for outpatient costs, and -0.19 to 0.93 for risk of 
hospitalization. The DRCI models predicted 7% and 9% of 
the variance in total and ambulatory costs, respectively. 
CONCLUSIONS: This study suggests an association between
clinical measures of diabetes severity and health care resource
and costs. Future studies are needed to validate this index in
other settings.
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OBJECTIVES: We determined rates of gastrointestinal (GI) 
complications among patients receiving nonsteroidal anti-
inﬂammatory drugs (NSAIDS), according to risk of GI events
and adherence to Veterans Affairs (VA) NSAID prescribing
guidelines; and calculated the associated costs of hospitalizations
from GI events by risk and adherence to guidelines. METHODS:
In November 2001, we identiﬁed 7625 patients treated with
NSAIDS in the New Mexico VA Health Care System. Using VA
prescribing guidelines we assessed each patient’s risk for GI
events (low, moderate, high) and whether their treatment
adhered to VA prescribing guidelines. We then reviewed patient
records for GI hospitalizations and diagnoses within the follow-
ing 2 years. Our data included demographic information, hos-
pitalizations, prescription medications, and diagnoses. Costs
were based upon 2002 Medicare reimbursement values. We com-
pared outcomes and costs by risk level and adherence to guide-
lines, using chi square analyses for categorical data and t-tests
for costs. RESULTS: Patients at moderate and high risk (n =
2288) had more (p < 0.001) GI hospitalizations (1.86%), com-
pared to patients at low risk (n = 5337, 0.83%) with an odds
ratio of 2.24, 95% conﬁdence interval 1.47–3.41. Adherence to
guidelines was not associated with fewer hospitalizations (odds
ratio 1.41, conﬁdence interval 0.67–2.96). Among patients at
moderate-risk who were hospitalized, non-adherence to criteria
(n = 26) was associated with higher (p = 0.027) mean costs
($5709 ± 2991) compared to those adherent to criteria (n = 9,
$4037 ± 1248). Additional hospitalization costs due to non-
adherence totaled $112,099. CONCLUSION: The VA guidelines
used to assess risk of GI complications from NSAIDS was 
related to rates of GI hospitalizations over a 2-year follow-
up period. Rates of hospitalizations were not affected by 
adherence to guidelines. However, mean hospitalization costs
were signiﬁcantly lower among patients at moderate risk who
were prescribed according to guidelines. Limitations are that 
the study is observational and that costs are limited to GI 
hospitalizations.
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With a prevalence in Western countries of around 15%, GORD
is associated with considerable long-term morbidity and treat-
ment costs. Since the introduction of laparoscopic surgery in the
1990s fundoplication has becomes a viable alternative to long-
term drug therapy in difﬁcult to treat patients. Partial fundopli-
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cation was developed as an alternative to the complete wrap in
order to reduce the prevalence of post-operative symptoms such
as bloating and dysphagia. OBJECTIVE: To systematically
review the effectiveness of two different surgical techniques of
laparoscopic fundoplication (partial versus total) for the treat-
ment of GORD in adults. METHODS: A systematic search of
the literature was carried out. All randomised trials comparing
total versus partial laparoscopic fundoplication were included.
The main outcome measure was the number of patients who
were symptom free at follow-up. Other outcome measures
reviewed included clinical outcomes, PROs and QoL. In addi-
tion any long-term follow-up data were reviewed. RESULTS:
Seven randomised trials identiﬁed met the inclusion criteria for
this review. All trials included compared laparoscopic total 
fundoplication compared to partial fundoplication. Post-trial
follow-up results varied between 3–6 months and a variety of
outcome measures were reported. One study reported 12-month
results. There was no reporting on quality of life, though three
trials reported PROs. Dysphagia was more frequently reported
in patients undergoing total fundoplication compared to partial
warp RR 2.82 [95% CI: 18.4, 4.32]. No signiﬁcant differences
in post-operative bloating was found between the two surgical
techniques. There was no signiﬁcant difference in the number of
patients reporting either “good” or “excellent” outcomes
between techniques RR 0.97 [95% CI: 0.89, 1.05]. CONCLU-
SIONS: Evidence from trials supports the view that both total
and partial fundoplication are clinically effective for treating
GORD. However, long-term efﬁcacy and QoL data are needed
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OBJECTIVES: To assess the cost-effectiveness of esomeprazole
(Nexium) compared to lansoprazole (Zoton FasTab) in the initial
treatment of reﬂux oesophagitis over 12 weeks from the per-
spective of the UK NHS. METHODS: A probabilistic decision
analysis model was constructed using Treeage DATATM 4.0 to
depict the sequential management of patients with unhealed
reﬂux oesophagitis. Treatment pathways were based on a pub-
lished 8-week UK healing model, however the model time
horizon was extended by an additional 4 weeks to ensure the
costs incurred by patients who remained unhealed after 8 weeks
were also included. Beta distributions for the 4 and 8 week
healing rates were calculated from a meta-analysis of the two
available head-to-head studies comparing esomeprazole 40mg (4
weeks - r = 2087, n = 2765; 8 weeks r = 342, n = 678) and lan-
soprazole 30mg (4 weeks - r = 1984, n = 2760; 8 weeks r = 347,
n = 776) in the healing of reﬂux oesophagitis. These studies used
the capsules formulation of lansoprazole. This data have been
used, as the capsule and oro-dispersible formulation are bioe-
quivalent. Triangular distributions were ﬁtted to utility values
reported by a study using the rating scale method in patients with
gastro-oesophageal reﬂux disease. Estimates of resource utilisa-
tion were obtained from a survey of UK-based clinicians, and
were multiplied by national published resource unit costs at
2003/04 prices. RESULTS: The mean cost per QALY gained with
esomeprazole and lansoprazole were £1482 and £1633 respec-
tively. Esomeprazole dominated lansoprazole (i.e. was more
effective and less expensive) in 86.8% of the 10,000 Monte
Carlo simulation patient iterations. Applying a willingness to 
pay threshold of £20,000 per QALY similar to that used by
NICE indicates that esomeprazole is cost-effective in 98.9% of
the 10,000 patient iterations. CONCLUSIONS: Esomeprazole 
is more cost-effective than the oro-dispersible formulation of 
lansoprazole in the initial treatment of reﬂux oesophagitis.
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OBJECTIVE: To determine the economic burden of liver cir-
rhosis, a common outcome of chronic hepatitis B, hepatitis C,
and alcoholic liver disease. METHODS: Hospital inpatient
admission records were analyzed for 1993–2001 in a health
insurance claims database (MarketScan® Database) for 3.5–5.0
million employees enrolled annually. All patients >18 years old
admitted with a primary diagnosis of cirrhosis (ICD-9-CM code
571.2 or 571.5) were included in the analysis. For each patient
identiﬁed, all admissions in a year were included except admis-
sions related to hepatocellular carcinoma, liver transplantation,
and admissions unlikely to be due to cirrhosis based on review
of all primary and secondary diagnoses for each admission. Cost
estimates were adjusted for inﬂation using the medical care com-
ponent of consumer price index and are reported in 2002 US$.
RESULTS: A total of 2073 cirrhosis patients with 4049 inpatient
admissions were identiﬁed during the 9-year period. The average
annual number of admissions per patient was 1.5 (95% conﬁ-
dence interval [CI]: 1.5–1.6); average length of hospital stay was
11.1 days (95% CI: 10.1–12.1), which decreased from 12.1 days
in 1995 to 8.1 days in 2000. The annual cost of inpatient care
per patient also decreased, from $31,244 in 1993 to $19,220 in
2000 for an average of $27,248 (95% CI: $24,247–$30,250);
86% (95% CI: 84%–87%) was for hospitalization and 7%
(95% CI: 6%–8%) for physician costs. CONCLUSIONS:
Annual cost of inpatient care for liver cirrhosis in the United
States is >$27,000 per patient hospitalized, more than twice the
average annual cost for all hospital admissions (~$12,000), and
nearly seven times the per capita annual medical care expenses
(~$4176). With >25,000 annual deaths from cirrhosis, this
causes substantial economic burden to society, and underscores
the need to prevent development of cirrhosis by preventing
hepatitis B, hepatitis C, and alcohol abuse.
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OBJECTIVES: A randomized, placebo-controlled trial demon-
strated sustained virological responses (SVR) exceeding 40% in
adult patients with PNALT/CHC using peginterferon alfa-2a
(40-kD) plus ribavirin (Peg/RBV) (Zeuzem. Hepatology 2003;
208A). We computed prognosis, costs, and cost-effectiveness of
